Copenhagen, 2011-08-10 10:59 CEST (GLOBE NEWSWIRE) -- Investor News
No. 11/2011
Notice of H1 2011 interim report and conference call
Copenhagen, 10 August 2011 - Zealand Pharma (ZEAL.CO), a biopharmaceutical company based in Denmark, will announce its H1 2011 Interim report on Thursday, 18 August 2011, expectedly around noon.
Conference call — Thursday, 18 August at 13:00 CEST/ 12:00 BST/ 07:00 EDT
Following release of the report, Zealand Pharma will host a conference call at 13:00 CET / 12:00 BST / 7:00 EST. David H. Solomon, President & Chief Executive Officer, Mats Blom, Chief Financial Officer, and Hanne Leth Hillman, Vice President for IR and Corporate Communication, will host the call to present the H1 report followed by a Q&A session. The conference call will be conducted in English and the dial-in numbers are:
DK +45 32 72 76 25
UK and international +44 (0) 145 255 5566
US +1 631 510 7498
Pass code for all participants: 8976 2445
An accompanying presentation will be available for download from the company's website (ir.zealandpharma.com) prior to the event. After the call, a replay of the event will also be made available on the website.
# # #
For further information, please contact:
Zealand Pharma A/S
Hanne Leth Hillman, Vice President, Investor Relations and Corporate Communication
Mobile: +45 5060 3689, e-mail: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S is a public (NASDAQ OMX: ZEAL) biopharmaceutical company based in Copenhagen, Denmark with a mature and growing clinical pipeline of innovative peptide based drugs. The company’s lead product is Lyxumia® (lixisenatide), a once-daily GLP-1 agonist licensed to Sanofi, which has Lyxumia® in late-stage Phase III development for the treatment of Type 2 diabetes. Zealand Pharma also has a collaboration with Boehringer Ingelheim covering glucagon/GLP-1 dual agonists, including ZP2929 for the treatment of diabetes and obesity, and a license agreement with Helsinn Healthcare on a clinical stage GLP-2 drug for the treatment of chemotherapy- and radiotherapy-induced diarrhea.
Zealand Pharma specializes in the discovery, optimization and development of novel peptide drugs with favorable therapeutic attributes, and all drug candidates in its pipeline have been identified through the company’s own drug discovery activities. Zealand Pharma’s products target disease areas where existing treatments fail to adequately serve patient needs and where the market potential for improved treatments through the use of peptide drugs is high.
For more information please visit www.zealandpharma.com
